What happened to the CSL (ASX:CSL) share price in October?

How did CSL shares perform last month? We take a closer look

| More on:
Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price kicked up a notch in October, nearing its 52-week high of $320.42. While the global biotech didn't release any market-sensitive news, investors appeared to be buying the company's shares.

They gained around 4% during October to end the month at $300.49.

At the time of writing, the CSL share price is $310.93, up 0.03% on the day. This means its shares are around 3% off breaking a new 52-week high and are up around 8% over the last month.

How did CSL fare last month?

During early October, CSL released the commentary around its annual general meeting (AGM).

Almost all of the information had already been divulged in previous market updates such as its full-year results in August. However, it didn't stop investors pushing up the CSL share price on the day to $292.68, a gain of 1.80%.

The surge came despite the S&P/ASX 200 Index (ASX: XJO) falling 0.26% to 7,280 points on the day.

CSL noted that it sees the current FY22 financial year as a transitional one. The board is confident the company can return to sustainable growth in the next 24 months. It has several major expansion projects underway along with developing its R&D pipeline products.

Nonetheless, there is still a strong demand for its portfolio of therapies and vaccines, which have offset plasma collection headwinds.

Plasma levels for FY21 were down about 20% on the previous year and these were collected at a higher cost per litre. This came from additional PPE and cleaning requirements, social distancing and labour costs as well as higher compensation paid to donors.

Most recently, a couple of brokers rated the company's shares following CSL's annual R&D day.

Multinational investment firm Goldman Sachs raised its price target by 1% to $305.00, while Jefferies had a more bullish outlook. The latter lifted its 12-month view by 3.1% to $338.00. Based on the current share price, this implies an upside of around 9% on Jefferies' assessment.

CSL share price review

When looking over the last 12 months, the CSL share price has gained around 6%. Year-to-date it has fared slightly better, up almost 10% for the period.

CSL presides a market capitalisation of roughly $141.49 billion, and has approximately 455.67 million shares on issue.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »